HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rowex launches OTC sumatriptan in Ireland

This article was originally published in OTC Bulletin

Executive Summary

Migraine sufferers in Ireland will for the first time be able to access a sumatriptan product without a prescription thanks to the OTC launch of Rowex’s Sumatran Relief.

You may also be interested in...



Second Time Lucky? Sumatriptan One Of Three Switches On The Cards In Germany

A second attempt at switching sumatriptan for migraines, as well as switch applications for non-steroidal anti-inflammatories ketoprofen and liquid ibuprofen, are all on the agenda at Germany's next Expert Committee for Prescription meeting in June. 

An Expert’s Guide To Switching In Germany, Part 1: Navigating The Reclassification Process

Elmar Kroth, scientific director of the German Medicines Manufacturers´ Association, the BAH, talks exclusively to HBW Insight about prescription-to-OTC switching in Germany and the association’s efforts to improve this process.

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel